A Study to Evaluate the Denosumab in Healthy Adults
Status:
Unknown status
Trial end date:
2019-12-28
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, parallel-group, placebo-controlled, single-dose
escalation Phase I study to evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics and immunogenicity of denosumab injection administered subcutaneously to
healthy adults in China
Phase:
Phase 1
Details
Lead Sponsor:
Luye Pharma Group Ltd.
Collaborators:
Shandong Boan Biotechnology Co., Ltd Shangdong Boan Biotechnology Co Ltd